Esperion Therapeutics (DE:0ET)
NASDAQ:0ET
0ET Stock Chart & Stats
€1.72
€0.27(14.05%)
At close: 4:00 PM EST
€1.72
€0.27(14.05%)
Day’s Range― - ―
52-Week Range€0.78 - €3.50
Previous CloseN/A
Volume200.00
Average Volume (3M)1.20K
Market Cap
€701.22M
Enterprise Value€747.22M
Total Cash (Recent Filing)€156.16M
Total Debt (Recent Filing)€252.63M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 04, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding257,693,360
10 Day Avg. Volume0
30 Day Avg. Volume1,195
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)-2.55
Price to Sales (P/S)1.91
P/FCF Ratio-58.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.52Price Target Upside46.51% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€333.90M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In High-risk PopulationsClinical evidence indicates bempedoic acid provides consistent benefit in specific high‑risk and statin‑intolerant patient groups, including a reduction in ischemic stroke risk, supporting targeted use where residual cardiovascular risk remains high.
Commercial Expansion And Pipeline DiversificationBroadened commercial efforts, international market entry plans, and acquisitions such as Corstasis aim to diversify the product portfolio and support deeper market penetration for Nexletol and Nexlizet.
Guideline EndorsementsUpdated national dyslipidemia guidelines granted bempedoic acid multiple strong recommendations and Class 1 distinctions, strengthening its role as a non‑statin option for patients unable to tolerate statins.
Bears Say
Direct Competitor With Superior EfficacyA competing oral cholesterol therapy from a major drugmaker demonstrated greater LDL lowering and fewer serious side effects in late‑stage data, creating a direct efficacy and tolerability challenge to bempedoic acid's market position.
Payer And Market Access ConstraintsPayers and large pharmaceutical partners possess scale and contracting leverage that could limit reimbursement and restrict uptake of branded bempedoic acid treatments, especially where out‑of‑pocket costs are a concern.
Shift In Prescriber PreferencesA trend toward prescribing therapies that produce larger cholesterol reductions and clearer links to clinical outcomes raises the risk that clinicians favor alternative agents over bempedoic acid, reducing long‑term commercial durability.
Esperion News
0ET FAQ
What was Esperion Therapeutics’s price range in the past 12 months?
Esperion Therapeutics lowest stock price was €0.78 and its highest was €3.50 in the past 12 months.
What is Esperion Therapeutics’s market cap?
Esperion Therapeutics’s market cap is €701.22M.
When is Esperion Therapeutics’s upcoming earnings report date?
Esperion Therapeutics’s upcoming earnings report date is Aug 04, 2026 which is in 55 days.
How were Esperion Therapeutics’s earnings last quarter?
Esperion Therapeutics released its earnings results on May 07, 2026. The company reported -€0.087 earnings per share for the quarter, missing the consensus estimate of -€0.032 by -€0.055.
Is Esperion Therapeutics overvalued?
According to Wall Street analysts Esperion Therapeutics’s price is currently Undervalued.
Does Esperion Therapeutics pay dividends?
Esperion Therapeutics does not currently pay dividends.
What is Esperion Therapeutics’s EPS estimate?
Esperion Therapeutics’s EPS estimate is >-0.01.
How many shares outstanding does Esperion Therapeutics have?
Esperion Therapeutics has 257,693,360 shares outstanding.
What happened to Esperion Therapeutics’s price movement after its last earnings report?
Esperion Therapeutics reported an EPS of -€0.087 in its last earnings report, missing expectations of -€0.032. Following the earnings report the stock price went down -0.911%.
Which hedge fund is a major shareholder of Esperion Therapeutics?
Currently, no hedge funds are holding shares in DE:0ET
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Esperion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€2.52 (46.51% Upside)
€2.52 (46.51% Upside)
Blogger Sentiment
Neutral
DE:0ET Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €88.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.19%
12-Months-Change
Fundamentals
Return on Equity
1.99%
Trailing 12-Months
Asset Growth
42.74%
Trailing 12-Months
Company Description
Esperion Therapeutics
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
0ET Company Deck
0ET Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial highlights: record revenue growth (Q4 +144%), meaningful U.S. product momentum (U.S. sales +38%; Rx equivalents +34%; prescribers +~25%), expanding international adoption (Daiichi +51% royalties; >700,000 patients treated), a stronger balance sheet ($167.9M cash and $55M debt paid), and a strategic acquisition (Corstasis/Enbumyst) that broadens market opportunity. Lowlights were largely transitional or one-time in nature: a large nonrecurring collaboration payment in 2025 that reduces revenue comparability in 2026, rising SG&A/legal costs tied to litigation, modestly higher R&D and operating expense guidance to fund integration and launches, and near-term uncertainty from guideline timing and competitive entrants. Overall, the positives — robust growth, global rollout, pipeline advancement, and a transformative acquisition — outweigh the manageable near-term challenges and one-time items.View all DE:0ET earnings summaries0ET Stock 12 Month Forecast
Average Price Target
€2.52
▲(46.51% Upside)
Technical Analysis
Options Prices
Currently, No data available
---